Tenaya Therapeutics Inc. (TNYA)
| Bid | 1.01 |
| Market Cap | 80.8M |
| Revenue (ttm) | 16.24M |
| Net Income (ttm) | -107.78M |
| EPS (ttm) | -1.44 |
| PE Ratio (ttm) | -0.71 |
| Forward PE | -0.85 |
| Analyst | Buy |
| Ask | 1.02 |
| Volume | 263,759 |
| Avg. Volume (20D) | 3,518,108 |
| Open | 1.02 |
| Previous Close | 1.01 |
| Day's Range | 0.98 - 1.02 |
| 52-Week Range | 0.86 - 7.01 |
| Beta | 2.85 |
About TNYA
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mut...
Analyst Forecast
According to 4 analyst ratings, the average rating for TNYA stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 1664.71% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · https://thefly.com
Tenaya Therapeutics price target lowered to $6 from $8 at LeerinkLeerink lowered the firm's price target on Tenaya Therapeutics to $6 from $8 and keeps an Outperform rating on the shares after the company announced initial Phase 1b/2 MyPEAK-1 data for TN-201 in MYB...